Jejunal adenocarcinoma, a rare cancer of the gastrointestinal tract: a comprehensive review discussion epidemiology

Abdul Mohammed1*, Prabhat Kumar2, Neethi Paranji1, Nithya Sritharan3 and Nisheet Waghray4

1Department of Gastroenterology and Hepatology, AdventHealth, Orlando, FL, USA
2Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland OH, 44111, USA
3Department of Hematology & Oncology, Rochester General Hospital, 1425 Portland Ave, Rochester, NY, 14621, USA
4Division of Gastroenterology and Hepatology, Metro Health Medical Center, Case Western Reserve University, 2500 Metrohealth Drive, Cleveland, OH, 44109, USA

Introduction

Malignancy of the small bowel is exceedingly rare, accounting for 3% - 5% of all gastrointestinal malignancies [1-3]. However, in recent years because of improved diagnostic accuracy, the incidence of small bowel cancer is rising. It is estimated that 10,470 new cases of primary SI cancer will be diagnosed in the US with 1450 cancer-related deaths [4]. The most frequent histologic types of small bowel malignant tumors include adenocarcinomas, carcinoids, lymphomas, and sarcomas. Adenocarcinoma of the small intestine is the second most common histologic type of SI cancer. The most frequent location of SI adenocarcinoma is the duodenum (57%), followed by the jejunum (29%) and ileum (13%) [5]. SI cancers are more common in men than women [6]. They occur more commonly in the African-American population and after 60 years of age [7].

There are several hypotheses to explain the relatively low incidence of SI cancers. Unlike the large intestine, a rapid transit time in the small intestine decreases exposure to luminal toxins and carcinogens. The presence of the enzyme benzopyrene hydroxylase in the intestinal mucosa aids in the detoxification and production of fewer reactive oxygen radicals in the small intestine. Further, bacterial enzymes also have oncogenic potential. A relatively low prevalence of bacteria in the small intestine is postulated to protect against carcinogenesis. The small intestine has one of the largest reserves of lymphoid tissue that confers immune surveillance against neoplastic cells. Finally, the rapid turnover of cells in the intestine is instrumental in clearing apoptotic bodies that have tumorigenic potential [8].

Risk factors

Lifestyle factors: Alcohol consumption, cigarette smoking, and dietary factors including a low-fiber diet and increased intake of processed meat and high-fructose-containing drinks are associated with increased odds of small bowel adenocarcinoma [9]. Alcohol use is associated with other gastrointestinal cancers of the esophagus, colon, and rectum [10]. It can interfere with DNA methylation, which influences cancer growth [11]. Since ethanol can also act as an irritant to the intestinal mucosa, it can increase susceptibility to carcinogens [12]. It has also been shown that acetaldehyde, the primary metabolite of ethanol, is genotoxic. In addition to alcohol, carcinogenesis with tobacco use occurs via several mechanisms. It can lead to the deposition of nitrosamines in the small intestine, a reduced cellular immune response, and impaired induction of enzymes that detoxify polycyclic aromatic hydrocarbons [13]. The resultant accumulation of reactive oxygen species predisposes cancer.

Familial syndromes

Several hereditary cancer syndromes can predispose to developing SI adenocarcinomas. Familial adenomatous polyposis (FAP) is a pre-cancerous condition associated with an increased risk of duodenal and periampullary neoplasms and early colorectal carcinoma requiring periodic surveillance. It is an autosomal dominant condition characterized by a
germline mutation in the APC gene, located on chromosome 5q21 [14]. APC is a member of the Wnt/B-catenin signaling pathway that is frequently implicated in colorectal cancer. When compared with the general population, patients with FAP are associated with an elevated relative risk (RR) of duodenal adenocarcinoma (RR, 331; 95% CI 132-681) [15]. Ruys, et al. described 3 cases of jejunal adenocarcinoma that developed in patients with FAP and advanced duodenal adenomatosis [16]. The same group later performed a prospective enteroscopic evaluation in 13 patients with FAP and advanced duodenal polyposis (Spielman stage IV). Only one patient was reported to have large polyps covering one-third of the jejunal circumference and the group concluded that clinically significant jejunal polyposis was rare and routine jejunal evaluation in FAP patients was not warranted [17]. Lynch syndrome or Hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant disease, occurs due to germline mutations in DNA mismatch repair (MMR) genes that can predispose to not only cancers of the small intestine but also colorectal, endometrial, gastric, ovarian, biliary, and skin [18]. It is associated with a 4% lifetime risk of developing small bowel neoplasia, which predominantly involves the distal small bowel [19]. Deficiency of the MMR gene results in microsatellite instability (MSI). The National Comprehensive Cancer Network (NCCN) endorses universal MMR or MSI testing of all patients with a personal history of SI adenocarcinoma to identify individuals with Lynch syndrome. Peutz-Jeghers syndrome (PJS) is an autosomal dominant condition caused by an inherited mutation of STK11. It is characterized by multiple hamartomatous and adenomatous gastrointestinal polyps, predominantly located in the jejunum and ileum [20,21]. At-risk individuals have a relative risk of 520 for developing SI adenocarcinoma when compared with unaffected individuals [22]. The lifetime risk of SI adenocarcinoma has been estimated between 1.7% and 13% for individuals with PJS [23,24].

**Crohn's disease and celiac disease**

Proinflammatory conditions like Crohn's disease and celiac disease can also predispose to SI adenocarcinoma through an adenoma-carcinoma sequence [25,26]. The risk of adenocarcinoma of the small intestine was modestly increased (10-fold) in a large population-based study of patients with celiac disease in Sweden [27]; however, the association with the celiac disease remains poorly understood. Crohn's disease is associated with adenocarcinoma of the distal small bowel, particularly the ileum. Von Roon, et al. described the relative risk of small intestinal cancer as 28.4 in patients with Crohn's disease, with a mean duration of nine years prior to the development of carcinoma [28]. There are case reports of an association between proinflammatory conditions and jejunal adenocarcinoma but no large-scale RCTs have been performed [29,30].

**Pathology and staging**

SI adenocarcinomas grossly appear as stenosing, ulcerative, infiltrative, or polypoid lesions (Figures 1,2). The histopathologic evaluation shows well to poorly differentiated tumors with a variable degree of mucin secretion. The American Joint Committee on Cancer (AJCC) stages SI adenocarcinoma in accordance with tumor size (T), regional lymphadenopathy (N), and the presence or absence of metastasis (M). Based on the extent of the disease, they are classified into 5 stages with tumor staging having a significant impact on survival; 72 months for stage I and stage II, 30 months for stage III, and 9 months for stage IV adenocarcinoma. The AJCC reported 5-year survival rates of 55% for stage I, 49% for stage II A, 35% for stage II B, 31% for stage III A, 18% for stage III B, and 5% for stage IV tumors [31].

**Clinical presentation and diagnosis**

Bridge, et al. described the clinical and pathological features of 32 adenocarcinomas of the jejunum [32]. Patients with jejunal adenocarcinoma may be asymptomatic or have non-specific symptoms such as intermittent abdominal cramping or pain, nausea, vomiting, or weight loss. Based on the size, location, and blood supply, adenocarcinomas of the jejunum can present with intestinal obstruction or occult gastrointestinal bleeding. At the time of diagnosis, more patients with jejunal adenocarcinoma are reported to be symptomatic when compared to duodenal adenocarcinoma (84% vs. 57%) [33]. Because of non-specific symptoms, there is a significant delay in diagnosing disease averaging 7 to 8 months from the onset of symptoms [34].
Several diagnostic modalities are available to evaluate small intestinal lesions. Barium studies are not particularly effective in identifying distal small intestinal lesions with a sensitivity of 50% [35]. In contrast, Computed tomography (CT) enterography and Magnetic resonance (MR) enterography have the advantage of providing multiplanar cross-sectional imaging over enteroclysis with a sensitivity of 100%. A prospective study comparing CT enterography to MR enterography in 150 patients with suspected small bowel disease reported that MR enterography was more accurate than CT enterography, particularly for neoplastic diseases ($p = .0412$) [36]. Video capsule endoscopy (VCE) and enteroscopy are the preferred diagnostic modalities to provide direct visualization of jejunal lesions. Zhang, et al. reported a higher detection rate of SI tumors with DBE when compared to VCE [37]. VCE allows complete visualization of the small bowel mucosa and is particularly effective in diagnosing lesions in patients with obscure GI bleeding with a detection rate of 4% to 9% [38]. In the case of small bowel obstruction or stricture, enteroscopy is the preferred diagnostic technique owing to the risk of capsule retention.

**Molecular mechanisms**

Genetic alterations in SI adenocarcinomas are not very well documented. K-ras mutations were more common in jejunal adenocarcinoma (43% to 47%), while p -53 mutations are more common in duodenal adenocarcinoma (41% to 48%) [39]. While ras genes regulate intracellular signaling pathways by encoding guanine nucleotide-binding proteins, K-ras activation has demonstrated oncogenic potential. Inactivation of p -53 tumor suppression genes and resultant deletion of chromosome 17p results in dysregulation of apoptosis. A mutation in the APC gene, a component of the Wnt/ B-catenin signaling pathway, that is frequently linked with colorectal cancer is seen as increasingly associated with peripancreatic tumors and duodenal adenocarcinomas. Microsatellite instability arising from a deficiency in the MMR gene in Lynch syndrome can be found in 5% to 35% of SI adenocarcinomas, predominantly affecting the distal small bowel [40].

**Prognosis**

Overall survival in SI adenocarcinoma is significantly correlated with tumor location, staging, age of the patient, surgical resection, and history of Crohn’s disease [47]. The most important independent prognostic factors on a multivariate analysis include curative resection (R0), lymph node involvement, and the ratio of positive to negative lymph nodes [48]. In patients undergoing curative resection, a poor prognosis was associated with patients who are older than 55 years of age, African-American heritage, duodenal or distal or diffuse tumor localization, advanced TNM stage, metastatic, poorly differentiated, or involved margins [49]. Several studies suggest that jejunal tumors have a better prognosis than duodenal tumors [1,41].

In conclusion, adenocarcinoma of jejunum is a rare cause of iron deficiency anemia. Considering its non-specific presenting symptoms, a high index of suspicion should be maintained, particularly when an EGD and colonoscopy do not exhibit the source of bleeding. Risk factors include environmental, familial, and chronic inflammatory conditions. Curative surgical resection is the treatment of choice for localized cancer, while systemic chemotherapy is reserved for advanced disease.

**References**


3. Aparicio T, Zaanan A, Svrcak M, Laurent-Puig P, Carrere N,


